Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$22.95 USD
+0.61 (2.73%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APLS 22.95 +0.61(2.73%)
Will APLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
Repligen (RGEN) Lags Q2 Earnings Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
Other News for APLS
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation
Apellis (APLS) Price Target Raised as Market Stabilizes
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News
Raymond James Adjusts Price Target for Apellis (APLS) After Q2 Earnings